| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_919b53d4d5c19382bded1ff8e5aa1627
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2acc0ab3e3d30a814bc655198932489 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-40 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2017-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb9b45a93f9d7f8347ad90da4d085dcb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4bb72fc341baced737b2381f89b3d89
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4ad81faf85e03450847d6dfd3e7e2e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43a13a35cd9bcb7bc4382a291448611a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72cb2ef273ecebafb95320a8f32c4fcb |
| publicationDate |
2020-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020270358-A1 |
| titleOfInvention |
Afucosylated monoclonal antibody |
| abstract |
Provided is an afucosylated monoclonal antibody. The monoclonal antibody is a human IgG antibody and has an afucosylated sugar chain structure at a heavy-chain sugar chain binding site. Also provided are application of the monoclonal antibody in the preparation of antineoplastic drugs, and a composition containing the monoclonal antibody. Compared with a fucosylated monoclonal antibody, the provided afucosylated monoclonal antibody has higher biological activity in vitro and in vivo and can be used for developing more effective therapeutic monoclonal antibody drugs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022200390-A3 |
| priorityDate |
2016-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |